UBS Group
INBX icon

UBS Group’s Inhibrx INBX Stock Holding History

UBS Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Sell
35,019
-13,118
-27% -$1.31M ﹤0.01% 4599
2026
Q1 		$3.24M Sell
48,137
-25,562
-35% -$1.9M ﹤0.01% 4513
2025
Q4 		$5.82M Buy
73,699
+64,273
+682% +$4.38M ﹤0.01% 3876
2025
Q3 		$317K Sell
9,426
-36,558
-80% -$900K ﹤0.01% 6401
2025
Q2 		$656K Buy
45,984
+18,516
+67% +$239K ﹤0.01% 5787
2025
Q1 		$384K Buy
27,468
+9,711
+55% +$132K ﹤0.01% 6066
2024
Q4 		$273K Buy
17,757
+11,716
+194% +$178K ﹤0.01% 6257
2024
Q3 		$94.6K Buy
6,041
+2,836
+88% +$39.8K ﹤0.01% 6415
2024
Q2 		$45.4K Buy
+3,205
New +$50.1K ﹤0.01% 6763

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's INBX Position: Q2 2026 in Review

UBS Group reduced its Inhibrx (INBX) stake by 27% in Q2 2026, selling an estimated $1.31M and leaving 35,019 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #4599.

UBS Group first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.82M in Q4 2025. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • UBS Group held 35,019 shares of Inhibrx worth $3.32M as of Q2 2026.
  • UBS Group sold 13,118 Inhibrx shares in Q2 2026, an estimated $1.31M.
  • Inhibrx made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4599 holding.
  • UBS Group first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • UBS Group's Inhibrx position peaked at $5.82M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.